Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles

Microtubule-targeting agents (MTAs) represent one of the most successful first-line therapies prescribed for cancer treatment. They interfere with microtubule (MT) dynamics by either stabilizing or destabilizing MTs, and in culture, they are believed to kill cells via apoptosis after eliciting mitot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Linda Wordeman, Juan Jesus Vicente
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	microtubules (MTs) microtubule-targeting agent (MTA) pathogen tauopathies cancer migration Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7d109383dac147d292134b4c2ce57858
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d109383dac147d292134b4c2ce57858
record_format	dspace
spelling	oai:doaj.org-article:7d109383dac147d292134b4c2ce578582021-11-25T17:02:17ZMicrotubule Targeting Agents in Disease: Classic Drugs, Novel Roles10.3390/cancers132256502072-6694https://doaj.org/article/7d109383dac147d292134b4c2ce578582021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5650https://doaj.org/toc/2072-6694Microtubule-targeting agents (MTAs) represent one of the most successful first-line therapies prescribed for cancer treatment. They interfere with microtubule (MT) dynamics by either stabilizing or destabilizing MTs, and in culture, they are believed to kill cells via apoptosis after eliciting mitotic arrest, among other mechanisms. This classical view of MTA therapies persisted for many years. However, the limited success of drugs specifically targeting mitotic proteins, and the slow growing rate of most human tumors forces a reevaluation of the mechanism of action of MTAs. Studies from the last decade suggest that the killing efficiency of MTAs arises from a combination of interphase and mitotic effects. Moreover, MTs have also been implicated in other therapeutically relevant activities, such as decreasing angiogenesis, blocking cell migration, reducing metastasis, and activating innate immunity to promote proinflammatory responses. Two key problems associated with MTA therapy are acquired drug resistance and systemic toxicity. Accordingly, novel and effective MTAs are being designed with an eye toward reducing toxicity without compromising efficacy or promoting resistance. Here, we will review the mechanism of action of MTAs, the signaling pathways they affect, their impact on cancer and other illnesses, and the promising new therapeutic applications of these classic drugs.Linda WordemanJuan Jesus VicenteMDPI AGarticlemicrotubules (MTs)microtubule-targeting agent (MTA)pathogentauopathiescancermigrationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5650, p 5650 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	microtubules (MTs) microtubule-targeting agent (MTA) pathogen tauopathies cancer migration Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	microtubules (MTs) microtubule-targeting agent (MTA) pathogen tauopathies cancer migration Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Linda Wordeman Juan Jesus Vicente Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
description	Microtubule-targeting agents (MTAs) represent one of the most successful first-line therapies prescribed for cancer treatment. They interfere with microtubule (MT) dynamics by either stabilizing or destabilizing MTs, and in culture, they are believed to kill cells via apoptosis after eliciting mitotic arrest, among other mechanisms. This classical view of MTA therapies persisted for many years. However, the limited success of drugs specifically targeting mitotic proteins, and the slow growing rate of most human tumors forces a reevaluation of the mechanism of action of MTAs. Studies from the last decade suggest that the killing efficiency of MTAs arises from a combination of interphase and mitotic effects. Moreover, MTs have also been implicated in other therapeutically relevant activities, such as decreasing angiogenesis, blocking cell migration, reducing metastasis, and activating innate immunity to promote proinflammatory responses. Two key problems associated with MTA therapy are acquired drug resistance and systemic toxicity. Accordingly, novel and effective MTAs are being designed with an eye toward reducing toxicity without compromising efficacy or promoting resistance. Here, we will review the mechanism of action of MTAs, the signaling pathways they affect, their impact on cancer and other illnesses, and the promising new therapeutic applications of these classic drugs.
format	article
author	Linda Wordeman Juan Jesus Vicente
author_facet	Linda Wordeman Juan Jesus Vicente
author_sort	Linda Wordeman
title	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
title_short	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
title_full	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
title_fullStr	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
title_full_unstemmed	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles
title_sort	microtubule targeting agents in disease: classic drugs, novel roles
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/7d109383dac147d292134b4c2ce57858
work_keys_str_mv	AT lindawordeman microtubuletargetingagentsindiseaseclassicdrugsnovelroles AT juanjesusvicente microtubuletargetingagentsindiseaseclassicdrugsnovelroles
_version_	1718412785507893248

Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles

Ejemplares similares